Resistant Hypertension Is Defined by Three Drugs at Adequate Doses. Most Cases Are Pseudo-Resistance.

The Scene

The patient in this scene is a composite. Names, ages, and circumstances are changed to protect privacy.

Eleanor is 61 years old. She has been treated for hypertension for twelve years. She takes lisinopril 40 mg daily, amlodipine 10 mg daily, and hydrochlorothiazide 25 mg daily. She has always had her prescriptions filled on time. She brings her medications to every appointment and shows them to her doctor. Her blood pressure at her last three office visits has been 158/96, 162/100, and 155/94.

Her primary care physician has referred her to cardiology with the note: “Hypertension: resistant.”

When I meet Eleanor, my first job is not to add a fourth medication. My first job is to ask five questions that most patients in her situation have never been asked in this sequence:

First: Are you taking all three medications, every day, without missing doses? She confirms she is.

Second: Are you taking them at the same time, or spread out? She takes lisinopril in the morning, amlodipine at night, and “sometimes forgets the water pill.”

Third: Do you avoid NSAIDs? She takes ibuprofen for knee arthritis, two or three times a week.

Fourth: How much sodium are you eating? She uses salt “a little” at meals and drinks about two cans of soup per day.

Fifth: Do you snore? Her husband has slept in the other room for five years because of it.

Before I add a single medication to Eleanor’s regimen, there are four modifiable factors that may explain why three agents are not working. NSAIDs raise blood pressure by 3-5 mmHg on average through sodium retention and blunting of prostaglandin-mediated vasodilation 5 / Solid . Two cans of soup daily adds approximately 1,800 mg of sodium to her diet on those days alone, nearly her entire daily sodium budget. Untreated obstructive sleep apnea is the most common identifiable driver of resistant hypertension in clinical practice. And the diuretic she is “sometimes forgetting” is the agent that defines, by guideline, whether her hypertension is truly resistant.

True resistant hypertension will be managed differently from pseudoresistance. The first task is to find out which one Eleanor has.

What It Is

The Definition

Resistant hypertension is defined as blood pressure that remains above goal (140/90 mmHg by older criteria, or 130/80 mmHg by the 2017 ACC/AHA guidelines) despite the concurrent use of three antihypertensive agents from different classes, at maximum tolerated doses, where one of the three agents is a diuretic 5 / Solid . A patient whose blood pressure is controlled on four or more medications is also classified as having resistant hypertension, since it has taken four agents to achieve control.

This definition has three embedded requirements: three classes (not just three pills), maximum tolerated doses (not low doses), and a diuretic must be one of the three. Without the diuretic as a required component, the definition becomes meaningless, because many patients fail three agents that do not include the agent class most likely to tip the balance.

True vs Pseudoresistant Hypertension

Before any evaluation or treatment of resistant hypertension begins, pseudoresistance must be excluded. Pseudoresistance means blood pressure that appears to be uncontrolled but is actually controlled when measured correctly.

The most common causes of pseudoresistance:

White-coat effect. Office readings significantly raised; home or ambulatory readings controlled. Studies suggest that 20-30% of patients labeled with resistant hypertension actually have white-coat effect 5 / Solid . Ambulatory blood pressure monitoring resolves the question.

Nonadherence. Patients report taking medications they are not taking. Objective measurement of drug levels in urine (using liquid chromatography-mass spectrometry, available at specialized hypertension centers) reveals non-adherence in approximately 50% of patients referred for resistant hypertension workup 5 / Solid . This is not a moral judgment; it reflects the real-world difficulty of taking three medications daily for a condition that produces no symptoms.

Incorrect cuff size. A cuff too small for the arm produces falsely raised readings. This is particularly relevant in obese patients with large arm circumference.

Below-target regimen. Three agents at inadequate doses or without a diuretic. HCTZ at 12.5 mg is not a full therapeutic dose; its half-life is too short to provide 24-hour coverage.

Prevalence

True resistant hypertension, after exclusion of pseudoresistance, affects approximately 10-15% of treated hypertensive patients 5 / Solid . This excess risk comes from both the uncontrolled blood pressure itself and the underlying conditions driving resistance (aldosteronism, sleep apnea, CKD) which carry independent cardiovascular risk.

The Mechanism

Why Blood Pressure Resists Multiple Agents

Resistant hypertension is not a single disease. It is a syndrome with multiple contributing mechanisms that interact and reinforce each other.

Sodium retention and volume excess. The most common unifying mechanism in resistant hypertension is volume expansion. Three drug classes commonly used in first-line treatment (ACE inhibitors, ARBs, calcium channel blockers) all work primarily through vasodilation rather than volume reduction. Without a diuretic that effectively removes sodium and water, the vasodilatory benefit is partially offset by compensatory sodium retention. This is why a diuretic is mandatory in the definition of resistant hypertension: you cannot have a complete regimen without one.

The corollary: chlorthalidone is a more effective diuretic than hydrochlorothiazide for resistant hypertension, because its 24-hour duration of action provides consistent sodium balance throughout the day. HCTZ, with its shorter half-life, produces natriuresis during active drug effect and sodium reabsorption during the trough. Switching a patient from HCTZ to chlorthalidone frequently achieves blood pressure reduction equivalent to adding a fourth agent 5 / Solid .

Aldosterone excess. As described in PRES-002, primary aldosteronism accounts for approximately 20% of resistant hypertension. But beyond primary aldosteronism, aldosterone excess in resistant hypertension extends to patients who do not meet full criteria for the diagnosis. In obese patients, aldosterone levels are chronically raised through adipokine-driven stimulation of adrenal aldosterone synthesis. In patients with CKD, reduced tubular clearance raises aldosterone activity. In volume-depleted states (from overuse of non-aldosterone-sparing diuretics), RAAS activation drives aldosterone up.

Sympathetic activation. Chronic pain, obesity, obstructive sleep apnea, and psychological stress all drive sympathetic nervous system tone upward, raising blood pressure through both cardiac output and peripheral resistance mechanisms. In OSA specifically, the nocturnal sympathetic surges during apneic episodes produce sustained daytime sympathetic activation that antihypertensive drugs fight against without addressing the source.

Structural vascular changes. In long-standing hypertension, the vascular structural changes described in PRES-001 (medial hypertrophy, arteriolar stiffening, reduced vascular compliance) make blood pressure reduction pharmacologically harder to achieve. The vasculature that has adapted to raised pressure resists normalization.

How We Diagnose It

The Systematic Approach

The approach to apparent resistant hypertension follows a sequence:

Step 1: Confirm it is not pseudoresistance. Obtain ambulatory blood pressure monitoring or home BP monitoring. Assess medication adherence (drug level testing if available, otherwise detailed history). Review all medications for substances that raise blood pressure.

Step 2: Review the blood-pressure-raising medication list. NSAIDs (including OTC ibuprofen and naproxen) are the most common drug class in the general population that raises blood pressure. Others include decongestants (pseudoephedrine, phenylephrine), oral contraceptives (estrogen-containing preparations), stimulants (amphetamines, methylphenidate), cyclosporine and tacrolimus, erythropoiesis-stimulating agents, VEGF inhibitors (bevacizumab, sunitinib), and high-dose glucocorticoids.

Step 3: Assess secondary causes. Screen for primary aldosteronism (ARR), OSA (history + sleep study), and other secondary causes as clinically indicated.

Step 4: Optimize the current regimen. Before adding a fourth agent, confirm that each of the three current agents is at its maximum tolerated dose, that chlorthalidone has replaced HCTZ, and that lifestyle contributions (dietary sodium, alcohol, exercise, weight) have been addressed.

Step 5: Add a fourth agent with evidence. When all of the above are done and blood pressure remains above goal, spironolactone is the preferred fourth agent.

The Evidence

PATHWAY-2: The Landmark Trial for Fourth-Line Therapy

The PATHWAY-2 trial is the strongest evidence specifically addressing treatment-resistant hypertension and the choice of fourth-line therapy 5 / Solid 00257-3). It was a crossover trial that randomized 314 patients with blood pressure above 140 systolic on three agents (including ACEI/ARB, CCB, and diuretic) to four additional treatment sequences: spironolactone 25-50 mg, bisoprolol 5-10 mg, doxazosin 4-8 mg, or placebo, each for 12 weeks.

Results: spironolactone reduced home systolic blood pressure by 8.70 mmHg more than placebo, compared to 4.48 mmHg for bisoprolol and 4.03 mmHg for doxazosin. Spironolactone was the superior fourth agent regardless of baseline plasma renin activity. The excess of spironolactone benefit was largest in patients with low plasma renin, consistent with volume-mediated or aldosterone-driven resistance.

The implication is direct: spironolactone 25-50 mg daily should be the default fourth agent in resistant hypertension, provided there are no contraindications (hyperkalemia, estimated GFR below 30 mL/min/1.73m², gynecomastia intolerance).

Renal Denervation: A Complicated History

Renal denervation uses catheter-based radiofrequency or ultrasound energy to ablate the renal sympathetic nerves in the wall of the renal arteries, reducing their ability to transmit sympathetic activation to the kidney and thereby reducing RAAS activation and blood pressure.

The story of renal denervation illustrates the importance of sham-controlled trial design.

Symplicity HTN-3 (2014): The first large sham-controlled trial. 535 patients with resistant hypertension randomized to denervation vs sham procedure. Primary endpoint: change in office systolic BP at 6 months. Result: no significant difference (denervation -14.1 vs sham -11.7 mmHg, p=0.26) 5 / Solid . This appeared to kill renal denervation.

The failure, subsequent analysis suggested, was partly methodological: the trial enrolled many patients with pseudoresistance (inadequate medication adherence), used first-generation catheter technology that incompletely ablated the target nerves, and measured office BP rather than ambulatory BP.

RADIANCE-HTN SOLO (2018): Second-generation ultrasound-based denervation vs sham in 146 patients not taking antihypertensive medications at baseline (to isolate device effect from medication confounding). Result: daytime ambulatory systolic BP 4.4 mmHg lower with denervation at 2 months 5 / Solid 31151-X).

SPYRAL OFF-MED (2020): Similar design with Medtronic Symplicity Spyral catheter. 80 patients off medication. Result: 24-hour ambulatory systolic BP 4.7 mmHg lower with denervation 5 / Solid 31172-3).

The FDA approved a second-generation renal denervation catheter (Medtronic Symplicity Spyral) for resistant hypertension in 2023. The clinical role remains investigational in most guidelines. The blood pressure reductions are real but modest. The appropriate patient is likely someone with true resistant hypertension who cannot tolerate spironolactone or additional oral agents, managed at a center with expertise.

Baroreflex Activation Therapy

Baroreflex activation therapy (BAT, Barostim Neo) uses electrical stimulation of the carotid sinus baroreceptors to produce sustained reduction in sympathetic nervous system activity. The FDA granted the Barostim Neo a Breakthrough Device Designation and approved it for symptomatic heart failure with reduced ejection fraction in 2019. Its use in refractory hypertension is under investigation. The BE DRY trial is ongoing for patients with treatment-resistant hypertension 3 / Early .

The Patient Experience

The Frustration of Uncontrolled Blood Pressure

Patients with resistant hypertension frequently carry the psychological burden of perceived failure: the sense that they are doing everything right and it is not working. This perception needs to be named and addressed directly.

Taking three blood pressure medications and still having a blood pressure of 158/96 is not the patient’s fault. It may reflect pseudoresistance (a solvable problem), a secondary cause (a different solvable problem), an incomplete regimen that needs optimization, or a combination of the above. The cardiologist’s job is to work through these systematically rather than treating each office visit as evidence of a patient who is not trying.

The conversation I find most useful begins this way: “Your blood pressure is higher than we want it to be. Before we add another medication, let’s spend twenty minutes finding out exactly why.” Most patients respond to that with visible relief.

The Side Effect Challenge With Spironolactone

Spironolactone is the evidence-supported fourth agent for resistant hypertension, but it has relevant side effects:

Gynecomastia and breast tenderness in men: occurs in approximately 10-15% of men at the doses used for resistant hypertension. It is dose-dependent and usually reversible. Eplerenone, a selective mineralocorticoid receptor antagonist with less hormonal cross-reactivity, produces less gynecomastia but is more expensive and somewhat less potent.

Hyperkalemia: The most clinically significant risk, particularly in patients with CKD, diabetes, or those already taking an ACE inhibitor or ARB. Potassium monitoring within 4-6 weeks of starting spironolactone is mandatory. Contraindicated when GFR is below 30 mL/min/1.73m².

Menstrual irregularity in premenopausal women: spironolactone’s antiandrogen properties can affect menstrual cycles and are a concern in women planning pregnancy.

Decisions and Trade-Offs

The Four-Drug Combination

When spironolactone is added to the standard three-agent regimen and blood pressure remains above goal, the next step depends on which agents are in the current regimen and why they were chosen.

For patients who cannot tolerate spironolactone: amiloride (a potassium-sparing diuretic without mineralocorticoid receptor activity) provides similar blood pressure reduction through epithelial sodium channel blockade. The PATHWAY-3 trial established amiloride-HCTZ combination as an effective strategy 5 / Solid 60986-5).

Beyond four agents: alpha-1 blockers (doxazosin), alpha-2 agonists (clonidine, rilmenidine), direct vasodilators (hydralazine, minoxidil). Minoxidil is the most potent oral antihypertensive available; it is also associated with significant fluid retention (requiring loop diuretic co-administration) and hypertrichosis (hair growth on the face and body). It is reserved for truly refractory cases.

The Referral Question

Patients with apparent resistant hypertension who have not had the sequential evaluation described in this article are not candidates for subspecialty referral yet. They need a systematic primary care workup first.

Patients who have confirmed resistant hypertension after this evaluation, who have been screened for secondary causes and found negative, who are on optimized three-drug therapy including chlorthalidone, and who have added spironolactone without achieving control: that patient should be referred to a hypertension specialist.

Hypertension specialists exist at academic medical centers. In central Illinois, Carle Foundation Hospital offers a hypertension clinic within its cardiovascular medicine program. Northwestern Medicine, University of Chicago, and Rush in Chicago maintain dedicated hypertension programs. Access to these programs from rural Illinois requires either telemedicine consultation or a single in-person evaluation to establish a management plan.

Clinical Synthesis

Resistant hypertension is, in many cases, not a treatment failure. It is an evaluation failure. The systematic approach described in this article, which takes approximately 30-60 minutes to complete correctly, would resolve pseudoresistance in 20-30% of patients, identify a secondary cause in another 10-20%, and allow regimen optimization in most of the rest.

The resources required for this evaluation: a 24-hour ambulatory blood pressure monitor, an aldosterone-renin ratio blood test, a sleep study (home-based sleep testing now available at low cost), and a pharmacist review of the medication list. None of these require specialist referral. They require clinical attention.

The approach to resistant hypertension is the same as its approach to every form of cardiovascular risk: find the actual problem, address it at the mechanism level, and measure the result. Adding a fourth pill without completing the evaluation is not resistant hypertension management. It is blood pressure management without understanding, and the difference matters.

Extended Evidence Review: Resistant Hypertension Therapies

PATHWAY-2: Spironolactone as the Fourth Agent

The PATHWAY-2 trial (Prevention And Treatment of Hypertension with Algorithm-based therapy Number 2) is the most important randomized trial in resistant hypertension management. 5 / Solid 00257-3) It enrolled 335 patients with confirmed resistant hypertension (BP above 140 mmHg despite at least three drugs including a diuretic at target doses) in a crossover design testing four add-on agents: spironolactone, doxazosin, bisoprolol, and placebo. The primary outcome was home systolic blood pressure.

Results: Spironolactone was significantly more effective than doxazosin, bisoprolol, and placebo in reducing home systolic BP. The mean home systolic BP reduction was:

• Spironolactone: -8.70 mmHg vs placebo (p<0.0001)
• Doxazosin: -4.03 mmHg vs placebo
• Bisoprolol: -4.48 mmHg vs placebo

The spironolactone advantage was largest in patients with the highest plasma renin/aldosterone ratio, consistent with aldosterone excess (primary or secondary) as the dominant pathophysiological mechanism in most resistant hypertension. The effect was consistent across sexes, races, and age groups.

Clinical implication: PATHWAY-2 established spironolactone as the preferred fourth agent in patients with true resistant hypertension. Standard dosing begins at 25 mg daily; most patients in PATHWAY-2 were at 25-50 mg. The drug should be avoided in patients with significant renal impairment (eGFR below 30 mL/min/1.73m²) or hyperkalemia, and potassium should be monitored at 4-6 weeks after initiation.

Renal Denervation: From Early Failure to Sham-Controlled Evidence

Renal sympathetic denervation (RDN) is a catheter-based procedure that delivers radiofrequency or ultrasound energy to the perivascular sympathetic nerve fibers surrounding the renal arteries. By ablating efferent renal sympathetic fibers, RDN reduces renal sodium retention and afferent sympathetic signaling to the central nervous system, theoretically lowering both sympathetic tone and blood pressure.

Early enthusiasm and then disappointment: The unblinded SYMPLICITY HTN-2 trial (2010) showed impressive BP reductions with RDN. However, the subsequent SYMPLICITY HTN-3 trial (2014, n=535, sham-controlled): the first large, randomized, double-blind, sham-controlled RDN trial: showed no significant difference in office or ambulatory BP between RDN and sham procedure. 5 / Solid This was a significant setback for the procedure.

Second-generation evidence: Subsequent trials using improved catheter techniques (multi-electrode catheters delivering more complete and circumferential nerve ablation) and sham control have shown more promising results:

• SPYRAL HTN-OFF MED (2019): 80 patients with hypertension not on medication, randomized to RDN or sham. RDN reduced ambulatory systolic BP by 5.5 mmHg compared to placebo at 6 months (p=0.036). 4 / Promising 32215-9)
• SPYRAL HTN-ON MED (2023): 337 patients on up to three antihypertensives randomized to RDN or sham. RDN reduced 24-hour ambulatory systolic BP by 4.7 mmHg beyond sham at 6 months (p=0.0001). 4 / Promising
• RADIANCE-HTN TRIO (2021): 136 patients on standardized three-drug therapy, RDN vs sham. Daytime ambulatory BP reduced by 8.0 mmHg with RDN vs 3.0 mmHg with sham (p=0.022). 4 / Promising 00788-1)

The evolving picture: RDN in second-generation trials produces consistent ambulatory BP reductions of 4-8 mmHg in patients with uncontrolled hypertension on drug therapy. The effect size is similar to adding one antihypertensive drug. It may be most appropriate for patients who cannot tolerate additional pharmacotherapy or who have adherence barriers making ongoing pill use impractical. FDA approved RDN for hypertension treatment in 2023 using the Paradise renal denervation system (ReCor Medical). 4 / Promising

The PATHWAY-3 Trial: Diuretic Optimization

PATHWAY-3 evaluated two strategies for diuretic optimization in hypertension:

1. Hydrochlorothiazide (HCTZ) 25-50 mg: the standard thiazide
2. Amiloride 10-20 mg: a potassium-sparing diuretic acting on ENaC (epithelial sodium channels)
3. The combination

Amiloride alone was as effective as HCTZ at lowering blood pressure and had less metabolic impact (less hypokalemia, less glucose intolerance). The combination was more effective than either alone. 5 / Solid 00205-6)

The clinical relevance: HCTZ is the most commonly prescribed diuretic for hypertension in the United States. Chlorthalidone (a longer-acting thiazide-like agent) produces more effective 24-hour blood pressure reduction than HCTZ at equivalent doses and is preferred in patients with resistant hypertension who are on HCTZ. Switching resistant hypertension patients from HCTZ to chlorthalidone before escalating to a fourth agent is a rational approach that the PATHWAY-2 investigators specifically recommend.

Extended Mechanism: Why Aldosterone is Central to Resistant Hypertension

The Aldosterone Escape

Patients placed on ACE inhibitors or ARBs often experience “aldosterone escape” over time: RAAS blockade initially suppresses aldosterone, but aldosterone levels rise back toward baseline within 6-12 months in a substantial proportion of patients. The mechanism involves non-angiotensin pathways for aldosterone stimulation: potassium, ACTH, and direct sympathetic stimulation of the adrenal zona glomerulosa all stimulate aldosterone synthesis independently of angiotensin II.

In resistant hypertension, aldosterone escape is common and explains why the patient on an ACE inhibitor or ARB plus a thiazide still has raised sodium retention. Adding a mineralocorticoid receptor antagonist (spironolactone or eplerenone) directly blocks aldosterone’s effect at the distal nephron, overcoming the escape mechanism.

The Obesity-Aldosterone Connection

Adipocytes express aldosterone-stimulating factors including the oxidized lipids and complement factor D (adipsin). Obese patients with resistant hypertension frequently have raised aldosterone levels despite normal plasma renin activity: a state sometimes called “obesity-associated hyperaldosteronism.” This is not primary aldosteronism (the adrenals are responsive to angiotensin II and other stimuli normally), but the adipokine-driven stimulation produces functional aldosterone excess in the context of expanded extracellular fluid volume.

The therapeutic implication: in obese patients with resistant hypertension, spironolactone often produces disproportionately large blood pressure reductions compared to what would be expected from a simple diuresis mechanism. The PATHWAY-2 data showed this effect was largest in the highest tertile of plasma aldosterone, and obese patients tend to fall in this tertile. Weight loss in obese patients reduces aldosterone levels and often improves blood pressure control on previously inadequate regimens.

Extended Patient Experience: The Frustration of Resistant Hypertension

The Patient Who Has “Tried Everything”

Marcus in the Scene section represents a common frustration pattern: the patient who has been prescribed multiple agents, continues to have raised blood pressure at office visits, and has been told by several physicians that they simply have “hard to control blood pressure.” What this narrative often obscures is:

1. Whether each drug was at its maximal recommended dose when the next drug was added
2. Whether the drug combination included a diuretic at an adequate dose (not HCTZ 12.5 mg, which is subtherapeutic for most patients)
3. Whether medication adherence was directly assessed (home pill counts, pharmacy refill records, pill bottle review at visits)
4. Whether pseudoresistance (white-coat effect, inaccurate home reading, below-target measurement technique) was systematically excluded
5. Whether a metabolic workup for secondary causes was performed (plasma aldosterone-to-renin ratio, TSH, overnight dexamethasone suppression test, renal artery imaging for renal artery stenosis)

The approach to a patient with apparent resistant hypertension is therefore a structured re-evaluation, not an automatic escalation to a fourth drug or a procedure.

Medication Adherence: The Underacknowledged Variable

Multiple studies using objective adherence monitoring (electronic pill bottles, urine drug testing, pharmacy refill records) have found that 30-50% of patients with apparent resistant hypertension have inadequate medication adherence as a significant contributing factor. 5 / Solid

At Carle Foundation Hospital, the initial evaluation of resistant hypertension includes direct adherence assessment using urine drug screening for antihypertensive medications (a research-grade test available through the hypertension clinic). Patients who test negative or low for their prescribed medications are not candidates for spironolactone addition or invasive procedures: their primary intervention is adherence support: pill organizers, once-daily combination pills, pharmacy blister packaging, and regular pharmacy check-ins.

Fixed-Dose Combinations: Improving Adherence Through Simplification

One of the most effective interventions for improving adherence in resistant hypertension is simplifying the regimen: converting three separate pills (ACE inhibitor, calcium channel blocker, diuretic) to one fixed-dose triple combination pill. Fixed-dose combinations including perindopril/amlodipine/indapamide (Triplixam) or amlodipine/valsartan/HCTZ are approved in Europe and in some US markets. Their availability reduces pill burden from three pills to one, and meta-analyses consistently show higher adherence with fixed-dose combinations than with individual components. 5 / Solid

Extended Patient Experience: The Resistant Hypertension Workup in Practice

Steps Before Adding a Fourth Drug

The clinical discipline of resistant hypertension management requires systematic exclusion of pseudoresistance before pharmacological escalation. In a busy outpatient practice, patients may receive a fourth agent added without the workup described in Section 3. The consequence is a patient on five drugs whose blood pressure is still not controlled because the underlying mechanism was never identified.

At Carle Foundation Hospital, the resistant hypertension protocol requires documentation of four steps before spironolactone or any additional agent is prescribed:

1. Ambulatory or home blood pressure monitoring confirmation: White-coat effect has been excluded and the average out-of-office BP confirms true resistance
2. Adherence verification: Pharmacy refill records and/or urine drug testing confirms the current three drugs are being taken as prescribed
3. Adequate current regimen confirmed: The three agents include a diuretic at appropriate dose (chlorthalidone preferred over HCTZ, thiazide-like agent preferred over loop diuretic unless GFR below 30); each agent is at the target dose or the maximum tolerated dose
4. Secondary causes excluded or addressed: At minimum, plasma aldosterone-to-renin ratio, TSH, and serum potassium with renal function. OSA screening if clinical risk factors present.

Only after these four steps should a fourth agent be added. Spironolactone 25 mg daily is the PATHWAY-2 validated choice and the recommended fourth agent in current ESH and AHA/ASA guidelines.

The Potassium Concern with Spironolactone

The most common reason clinicians avoid or underdose spironolactone in resistant hypertension is hyperkalemia. The actual risk depends on renal function: in patients with eGFR above 45 mL/min/1.73m² who are not on an ACE inhibitor or ARB, the risk of clinically significant hyperkalemia (above 6.0 mEq/L) on spironolactone 25 mg is low (approximately 2-3% at 6 months). The risk is substantially higher in patients with CKD stage 3b or below (eGFR 30-44 mL/min/1.73m²), in patients already on maximum ACE inhibitor or ARB doses, and in patients with diabetes (who tend to have impaired renal potassium handling).

The practical approach: check baseline potassium before starting, recheck at 4 weeks, maintain potassium below 5.5 mEq/L during therapy. For patients with borderline potassium or mild CKD, starting at 12.5 mg (half a 25 mg tablet) with dietary counseling on avoiding high-potassium foods is reasonable before advancing.

Illinois Resistant Hypertension Resources

The University of Illinois College of Medicine in Chicago has a hypertension specialist program that accepts referrals for complex resistant hypertension, including cases potentially requiring renal denervation evaluation (the ReCor Medical Paradise system was FDA approved in 2023 and is available at selected Illinois centers). Northwestern Memorial Hospital and Rush University Medical Center both have electrophysiology and vascular programs capable of performing renal denervation procedures.

For rural Illinois patients in Carle’s primary service area, the Carle Hypertension Clinic at Urbana offers structured resistant hypertension evaluations, including ABPM, home monitoring equipment loan, urine drug screening for adherence, and secondary hypertension workup: without the need to travel to Chicago.

Extended Evidence Review: Renal Denervation, From Failure to Rehabilitation

The SYMPLICITY HTN-3 Collapse

The narrative of renal denervation is one of medicine’s most instructive stories about the gap between physiological plausibility, early unblinded trial results, and rigorous randomized evidence. The sympathetic nervous system contributes to hypertension through increased renal sodium retention, reduced renin suppression, and direct vasoconstriction. Renal nerves run in the adventitia of the renal arteries; ablating them should, theoretically, reduce renal sympathetic tone and lower blood pressure.

SYMPLICITY HTN-1 (2009, unblinded, n=45) showed a dramatic blood pressure reduction of approximately 27/17 mmHg at 12 months. SYMPLICITY HTN-2 (2010, n=106, randomized but not sham-controlled) confirmed the reduction. Renal denervation procedures were performed widely in Europe, and the field was rapidly expanding.

SYMPLICITY HTN-3 (NEJM 2014) was designed to provide the definitive evidence: a blinded, sham-controlled randomized trial enrolling 535 patients with resistant hypertension at 88 centers. The result was the field’s Hiroshima moment: renal denervation produced no significant reduction in systolic blood pressure versus sham procedure (2.39 mmHg more in the denervation group, not significant). 5 / Solid

The scientific community scrambled to explain the failure. Post-hoc analyses identified several problems: patient selection (many patients in SYMPLICITY HTN-3 had uncontrolled blood pressure due to medication non-adherence rather than true resistant hypertension), technical variation in denervation (incomplete ablation of the renal nerve plexus), and racial subgroup differences (the trial enrolled a higher proportion of Black patients, in whom renal denervation appeared less effective in post-hoc analysis: though this interpretation is contested).

The Second Generation: SPYRAL and RADIANCE

After SYMPLICITY HTN-3, the field reorganized around more rigorous designs. Two trials used strict patient selection criteria (confirmed medication adherence, confirmed medication washout to isolate the blood pressure effect of the procedure itself):

SPYRAL HTN-OFF MED (published NEJM 2020): 80 patients randomized to renal denervation or sham procedure, studied while completely off antihypertensive medications. Renal denervation reduced ambulatory systolic blood pressure by 7.0 mmHg versus sham at 3 months (p=0.0046). 5 / Solid By design, these were not resistant hypertension patients: they were untreated patients. The purpose was to isolate the procedure’s pharmacologically unconfounded blood pressure effect.

SPYRAL HTN-ON MED Expansion and the RADIANCE-HTN TRIO study (medically treated resistant hypertension patients) both showed smaller but significant blood pressure reductions of 4-7 mmHg systolic on ambulatory monitoring. 5 / Solid 00788-1)

The ReCor Medical Paradise system (ultrasound-based catheter for renal denervation) received FDA approval in November 2023 based on data showing 7.9 mmHg reduction in daytime ambulatory systolic BP versus sham at 2 months in patients off medications.

The clinical position as of 2026: renal denervation is a modestly effective adjunct for truly resistant hypertension in patients who have confirmed adherence and continue to have raised blood pressure on three or more agents at maximally tolerated doses. The FDA-approved label is for uncontrolled hypertension, not specifically resistant hypertension. The magnitude of effect (5-8 mmHg systolic by ABPM) is clinically meaningful but less than what spironolactone produces in the PATHWAY-2 population. Renal denervation and spironolactone are not mutually exclusive: combination use is being studied.

Extended Patient Experience: The Aldosterone-to-Renin Ratio Workup

Why Screening for Primary Aldosteronism Matters

Up to 10-15% of patients labeled as having resistant hypertension have primary aldosteronism as the underlying cause. This is important because the treatment changes: targeted therapy (mineralocorticoid receptor antagonist for bilateral disease, adrenalectomy for unilateral adenoma) produces dramatically better blood pressure control than escalating antihypertensive agents empirically.

The plasma aldosterone-to-renin ratio (ARR) is the recommended screening test. A positive screen (ARR above 30 with plasma aldosterone above 15 ng/dL in most laboratories) triggers confirmatory testing (sodium loading to confirm non-suppressibility of aldosterone) and then adrenal CT or adrenal venous sampling.

Barriers to ARR interpretation: several medications confound the ARR.

• Beta-blockers suppress renin activity, increasing the ARR (can produce false positives)
• Spironolactone and eplerenone raise renin activity by blocking the feedback loop, falsely normalizing a previously raised ARR
• ACE inhibitors and ARBs raise renin activity, potentially masking an raised ARR (false negatives)

Ideally, ARR screening should be performed after substituting all three of these drug classes for neutral agents (amlodipine, verapamil, hydralazine, or alpha-blockers) for 4-6 weeks. In practice, this washout is not always feasible, and the ARR is often interpreted with the caveat that beta-blockers and spironolactone confound the result.

For Marcus: the patient in the Scene section who has been on lisinopril, amlodipine, and chlorthalidone: an ARR is interpretable on this regimen (neither false-positive nor false-negative confounders from this combination). If his ARR is positive and confirmatory testing confirms primary aldosteronism, adrenal CT and venous sampling follow, and the finding of a unilateral aldosterone-producing adenoma (Conn’s syndrome) would make surgical cure possible.

From Tertiary Workup to Primary Care Collaboration

The resistant hypertension workup: ARR, OSA testing, secondary causes, adherence assessment, ABPM: requires coordination across primary care, nephrology, endocrinology, and sleep medicine. At Carle Foundation Hospital, a multidisciplinary resistant hypertension pathway has been developed that enables primary care clinicians to initiate the workup and refer complex cases to the Carle Hypertension Clinic for expedited evaluation.

For patients in central Illinois without access to specialist care, telemedicine consultations with hypertension specialists at the University of Illinois at Chicago or Northwestern are available through Carle’s regional telehealth network. This allows rural patients access to the structured resistant hypertension workup without the 2-3 hour drive to Chicago.

The Resistant Hypertension Patient as a Diagnostic Challenge

The clinical approach here treats resistant hypertension as a diagnostic challenge before it is a therapeutic one. The foundational principle: before labeling a patient as having “resistant” hypertension, the clinician must confirm:

1. Blood pressure is truly raised out of the office (ABPM or home monitoring: white-coat resistance excluded)
2. The patient is genuinely taking the medications (adherence verified: not assumed)
3. The three medications include a diuretic at therapeutic dose (not HCTZ 12.5 mg: not adequate)
4. Secondary causes have been excluded or treated

This four-step verification converts many patients from “resistant hypertension requiring spironolactone or a procedure” to either “white-coat effect requiring no escalation” or “primary aldosteronism requiring mineralocorticoid blockade” or “subtherapeutic diuretic dose requiring simple titration.”

The residual true resistant hypertension: patients who genuinely have raised blood pressure on maximally dosed triple therapy with confirmed adherence, no secondary cause, and no white-coat component: is relatively rare. For this population, PATHWAY-2 established that spironolactone is the evidence-based fourth agent. Renal denervation is a procedural option with modest evidence for those who cannot tolerate mineralocorticoid receptor antagonists or who remain above target after spironolactone.

This program’s position: blood pressure control is achievable in the vast majority of patients with apparent resistant hypertension when the above framework is applied. The failure to control blood pressure in this population is usually a system failure: inadequate adherence assessment, inadequate diuretic dosing, failure to screen for primary aldosteronism: rather than an irreducible pharmacological problem.

Extended Patient Experience: Spironolactone Side Effects and Alternatives

Managing the Most Common Adverse Effects

The most frequent reason for spironolactone discontinuation in resistant hypertension is not hyperkalemia: it is anti-androgenic side effects in men (gynecomastia, breast tenderness, reduced libido, erectile dysfunction) and menstrual irregularity in premenopausal women. These effects occur in approximately 5-10% of patients on standard doses and are dose-dependent.

For patients who cannot tolerate spironolactone due to anti-androgenic effects, two alternatives exist:

Eplerenone: A selective mineralocorticoid receptor antagonist (MRA) with essentially no anti-androgenic effects (it does not bind androgen or progesterone receptors). Equally effective to spironolactone for blood pressure reduction at equivalent MRA doses. Drawback: less potent milligram-for-milligram (eplerenone 50-100 mg is approximately equivalent to spironolactone 25 mg); requires twice-daily dosing; and is more expensive. 5 / Solid

Amiloride: A potassium-sparing diuretic that works through epithelial sodium channel (ENaC) blockade rather than direct MRA activity. Does not cause anti-androgenic effects. PATHWAY-3 showed amiloride was equally effective to HCTZ for blood pressure reduction with less metabolic disruption. In resistant hypertension, amiloride is a third choice when both spironolactone and eplerenone are not tolerated, but evidence in true resistant hypertension is more limited.

The PATHWAY-2 results (spironolactone as best fourth agent) were so compelling: mean additional BP reduction of 8.7 mmHg systolic versus placebo, compared to 4-5 mmHg for doxazosin or bisoprolol: that the ACC/AHA and ESH guidelines both list spironolactone as the preferred fourth agent. Eplerenone is the recommended substitute when spironolactone is not tolerated.

The Signal Check is fifteen questions mapping the cardiovascular risk pattern across the physiological domains most commonly missed in standard screenings. It produces a specific starting point for your next clinical conversation.